Segment Data (Tables)

9 Months Ended

Jun. 30, 2017

Financial Information for Company's Segments

Financial information for the Company’s segments was as follows:



	Three Months Ended June 30,						Nine Months Ended June 30,
(Millions of dollars)	2017			2016			2017			2016
Revenues (A)
Medical	$	2,038		$	2,235		$	5,989		$	6,420
Life Sciences	997			963			2,937			2,832
Total Revenues	$	3,035		$	3,198		$	8,927		$	9,252
Income Before Income Taxes
Medical	$	553		$	571		$	1,638		$	1,549
Life Sciences	199			200			574			604
Total Segment Operating Income	751			771			2,212			2,152
Acquisitions and other restructurings	(81		)	(96		)	(243		)	(321		)
Net interest expense	(165		)	(92		)	(334		)	(279		)
Other unallocated items (B)	(909		)	(160		)	(985		)	(488		)
(Loss) Income Before Income Taxes	$	(404	)	$	422		$	650		$	1,065


(A)	Intersegment revenues are not material.

(B)

Primarily comprised of foreign exchange, corporate expenses, and share-based compensation expense. The amounts for the three and nine months ended June 30, 2017 also included a $741 million non-cash charge resulting from a modification to the Company's dispensing equipment lease contracts with customers. The amount for the nine months ended June 30, 2017 included a $336 million reversal of certain reserves related to an appellate court decision which, among other things, reversed an unfavorable antitrust judgment in the RTI case. Additional disclosures regarding the legal matter and the lease contract modification are provided in Notes 5 and 16, respectively.

Revenues by Geographic Areas

Revenues by geographic areas were as follows:



	Three Months Ended June 30,				Nine Months Ended June 30,
(Millions of dollars)	2017		2016		2017		2016
Revenues
United States	$	1,603	$	1,735	$	4,859	$	5,145
International	1,433		1,463		4,068		4,107
Total Revenues	$	3,035	$	3,198	$	8,927	$	9,252